BIRC5 and glioblastoma: Our findings indicate that a combination of alternative receptor usage, either through the use of pseudotyped or whole serotyped vectors, in combination with tumour-specific promoters such as survivin, may offer a powerful and highly selective means to deliver cytotoxic or immunostimulatory payloads selectively to GBM cells.